NCSTN

Across TCGA pan-cancer cohorts, NCSTN mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NCSTN data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NCSTN mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NCSTN expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where NCSTN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	18	view →
PDAC	DFS	Quartile	All	0.281	0.475	.015	12	view →
LSCC	DFS	Quartile	II,III,IV	0.976	0.834	.025	3	view →
LUAD	OS	Median	III,IV	0.818	0.271	.046	2	view →
HNSC	DFS	Quartile	III,IV	0.324	1.000	.049	2	view →
GBM	OS	Quartile	All	0.765	0.940	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NCSTN–CCRCC (DFS)

Open the CCRCC breakdown →